Local Institution

Los Angeles, California 90095

0 studies enrolling now · 40 studies all time

What they study most

AIDS, Advanced Cancer, Various, NOS, Advanced Cutaneous Melanoma, Alzheimer Disease, Arthritis, Rheumatoid, Bladder Cancer, Bladder Neoplasms, Blast Crisis, Breast Cancer, Cancer, Cancer of the Stomach, Chronic Myelogenous Leukemia

Studies at this site

• A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread — Completed
• A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma — Completed
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma — Withdrawn before enrolling
• A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease — Completed
• Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma — Completed
• Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis — Completed
• A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) — Withdrawn before enrolling
• Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase — Withdrawn before enrolling
• Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer — Completed
• Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients — Stopped early
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone — Completed
• Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise — Completed
• A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189) — Completed
• Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type — Completed
• Aripiprazole in Adolescents With Schizophrenia — Completed
• PPAR - Combination With Metformin — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma — Withdrawn before enrolling
• Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen — Completed
• Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) — Completed
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia — Completed
• A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes — Completed
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Atazanavir for HIV Infected Individuals: An Early Access Program — NO_LONGER_AVAILABLE
• BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia — Completed
• The Study of Abatacept in Combination With Etanercept — Completed
• A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics — Completed
• PPAR-COMBO With Sulfonylurea — Completed
• Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes — Completed
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium — Completed
• BMS-599626 in Patients With Advanced Solid Malignancies — Completed
• Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies — Stopped early
• Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen — Completed
• A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen — Completed
• Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early